Anderson Karen M.'s Form 4 filing
Centessa Pharmaceuticals plc (CNTA) · filed Mar 13, 2026
- Accession no.
- 0001470831-26-000268
- Filed
- Mar 13, 2026
- Trade date
- Mar 13, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.15M. It was filed on the trade date.
This filing was later replaced by the amendment 0001470831-26-000279 (Mar 16, 2026). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anderson Karen M.CIK 0001762176 | Officer (Chief People Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | Ordinary Shares | MOption exerciseAcquired | +109,398 | $4.01 | +$438,685.98 | 182,114 | Direct | |
| Mar 13, 2026 | Ordinary Shares | SSaleDisposed | −107,961 | $26.15F3 | −$2,823,180.15 | 74,153 | Direct | |
| Mar 13, 2026 | Ordinary Shares | SSaleDisposed | −12,068 | $27.13F4 | −$327,404.84 | 62,085 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | Ordinary Shares | MOption exerciseDisposed | −109,398 | $0.00 | $0 | 134,637 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.75 to $26.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.805 to $27.455, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.